Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties

Journal of Medicinal Chemistry

Volumn 42, Issue 18, 1999, Pages 3615-3622

  Christner, Claudia ^a   Wyrwa, Ralf ^b   Marsch, Silvia ^c   Küllertz, Gerhard ^a   Thiericke, Ralf ^b   Grabley, Susanne ^b   Schumann, Dieter ^c   Fischer, Gunter ^c  

^a MAX PLANCK RESEARCH UNIT FOR ENZYMOLOGY OF PROTEIN FOLDING   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; CYCLOHEXIMIDE N (ETHYL ETHANOATE); CYCLOPHILIN; ENZYME INHIBITOR; FK 506 BINDING PROTEIN; PROTEIN SYNTHESIS INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN SYNTHESIS; RAT; SCIATIC NERVE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CYCLOHEXIMIDE; ENZYME INHIBITORS; HUMANS; IMMUNOPHILINS; K562 CELLS; KINETICS; MICE; NERVE REGENERATION; PEPTIDYLPROLYL ISOMERASE; PIPERIDINES; RATS; SCIATIC NERVE; TACROLIMUS BINDING PROTEINS; TUMOR CELLS, CULTURED;

EID: 0033539160     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm991038t     Document Type: Article

References (86)

1. Fischer, G.; Bang, H.; Mech, C. Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides. [German] Biomed. Biochem. Acta 1984, 43, 1101-1111.
2. (a) Lang, K.; Schmid, X. F.; Fischer, G. Catalysis of protein folding by prolyl isomerase. Nature 1987, 329, 268-270.
3. (b) Schmid, F. X.; Mayr, L.; Mücke, M.; Schönbrunner, R. E. Prolyl isomerases: role in protein folding. Adv. Protein Chem. 1993, 44, 25-66.
4. (c) Schmid, F. X. Protein folding-prolyl isomerases join the fold. Curr. Biol. 1995, 5, 993-994.
5. (d) Fischer, G.; Tradler, T.; Zarnt, T. The mode of action of peptidyl prolyl cis/ trans isomerases in vivo: binding vs catalysis. FEBS Lett. 1998, 426, 17-20.
6. For recent reviews on cyclophilins and FKBPs and their effectors, see: (a) Fischer, G. Peptidyl-prolyl cis/trans isomerases and their effectors. Angew. Chem., Int. Ed. Engl. 1994, 33, 1415-1436.
7. (b) Galat, A.; Metcalfe, S. M. Peptidylproline cis/trans isomerases. Prog. Biophys. Mol. Biol. 1996, 63, 67-118.
8. (a) Rahfeld, J. U.; Schierhorn, A.; Mann, K.; Fischer, G. A novel peptidyl-prolyl cis/trans isomerase from Escherichia coli. FEBS Lett. 1994, 343, 65-69.
9. (b) Rahfeld, J. U.; Rücknagel, K. P.; Schelbert, B.; Ludwig, B.; Hacker, J.; Mann, K.; Fischer, G. Confirmation of the existence of a third family among peptidyl-prolyl cis/trans isomerases. Amino acid sequence and recombinant production of parvulin. FEBS Lett. 1994, 352, 180-184.
10. (c) Hennig, L.; Christner, C.; Kipping, M.; Schelbert, B.; Rücknagel, K. P.; Grabley, S.; Küllertz, G.; Fischer, G. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. Biochemistry 1998, 37, 5953-5960.
11. (a) Marks, A. R. Cellular functions of immunophilins. Physiol. Rev. 1996, 76, 631-649.
12. (b) Galat, A. Peptidylproline cis-trans-isomerases: immunophilins. Eur. J. Biochem. 1993, 216, 689-707.
13. (c) Stoller, G.; Rücknagel, K. P.; Nierhaus, K. H.; Schmid, F. X.; Fischer, G.; Rahfeld, J. U. A ribosome-associated peptidyl-prolyl cis/trans isomerase identified as the trigger factor. EMBO J. 1995, 14, 4939-4948.
14. (d) Hottenrott, S.; Schumann, T.; Plückthun, A.; Fischer, G.; Rahfeld, J.-U. The Escherichia coli SlyD is a metal ion-regulated peptidyl-prolyl-cis/trans-isomerase. J. Biol. Chem. 1997, 272, 15697-15701.
15. (e) Hacker, J.; Fischer, G. Immunophilins: structure-function relationship and possible role in microbial pathogenicity. Mol. Microbiol. 1993, 10, 445-456.
16. (a) Lu, K. P.; Hanes, S. D.; Hunter, T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996, 380, 544-547.
17. (b) Shen, M.; Stukenberg, P. T.; Kirschner, M. W.; Lu, K. P. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev. 1998, 12, 706-720.
18. (c) Hani, J.; Stumpf, G.; Domday, H. PTF1 encodes an essential protein in Saccharomyces cerevisiae, which shows strong homology with a new putative family of PPIases. FEBS Lett. 1995, 365, 198-202.
19. (d) Maleszka, R.; Hanes, S. D.; Hackett, R. L.; de Couet, H. G.; Miklos, G. L. The Drosophila melanogaster dodo (dod) gene, conserved in humans, is functionally interchangeable with the ESS1 cell division gene of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 447-451.
20. Kay, J. E. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem. J. 1996, 314, 361-385.
21. Smith, D. F.; Baggenstoss, B. A.; Marion, T. N.; Rimerman, R. A. Two FKBP-related proteins are associated with progesterone receptor complexes. J. Biol. Chem. 1993, 268, 18365-18371.
22. Wang, T.; Li, B.-Y.; Danielson, P. D.; Shah, P. C.; Rockwell, S.; Lechleider, R. J.; Martin, J.; Manganaro, T.; Donahoe, P. K. The immunophilin FKBP12 functions as a common inhibitor of the TGFβ family type I receptors. Cell 1996, 86, 435-444.
23. Lopez-Ilasaca, M.; Schiene, C.; Küllertz, G.; Tradler, T.; Fischer, G.; Wetzker, R. Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. J. Biol. Chem. 1998, 273, 9430-9434.
24. (a) Jayaraman, T.; Brilliantes, A. M.; Timerman, A. P.; Fleischer, S.; Erdjument-Bromage, H.; Tempst, P.; Marks, A. R. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J. Biol. Chem. 1992, 267, 9474-9477.
25. (b) Timerman, A. P.; Onoue, H.; Xin, H. B.; Barg, S.; Copello, L.; Wiederrecht, G.; Fleischer, S. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J. Biol. Chem. 1996, 271, 20385-20391.
26. (c) Cameron, A. M.; Steiner, J. P.; Sabatini, D. M.; Kaplin, A. I.; Walensky, L. D.; Snyder, S. H. Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1784-1788.
27. (d) Wagenknecht, T.; Radermacher, M.; Grassucci, R.; Berkowitz, J.; Xin, H.-B.; Fleischer, S. Locations of calmodulin and FK506-binding protein on the three-dimensional architecture of the skeletal muscle ryanodine receptor. J. Biol. Chem. 1997, 272, 32463-32471.
28. Shou, W.; Aghdasi, B.; Armstrong, D. L.; Guo, Q.; Bao, S.; Charng, M. J.; Mathews, L. M.; Schneider, M. D.; Hamilton, S. L.; Matzuk, M. M. Cardiac defects and altered ryanodine function in mice lacking FKBP12. Nature 1998, 391, 489-492.
29. Kino, T.; Hatanaka, H.; Hashimoto, M.; Nishiyama, M.; Goto, T.; Okuhara, M.; Kohsaka, M.; Aoki, H.; Imanaka, I. FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, physicochemical and biological characteristics. J. Antibiot. 1987, 40, 1249-1255.
30. Martel, R. R.; Klicius, J.; Galet, S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 1977, 55, 48-51.
31. (a) Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase, Nature 1989, 341, 758-760.
32. (b) Bierer, B. E.; Mattila, P. S.; Standaert, R. F.; Herzenberg, L. A.; Burakoff, S. J.; Crabtree, G.; Schreiber, S. L. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 9231-9235.
33. (a) Liu, J.; Farmer Jr., J. D.; Lane, S. W.; Friedman, J.; Weissman, I.; Schreiber, S. L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66, 807-815.
34. (b) McCaffrey, P. G.; Perrino, B. A.; Soderling, T. R.; Rao, A. NF-ATp, a T-lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J. Biol. Chem. 1993, 268, 3747-3752.
35. (c) Schreiber, S. L.; Crabtree, G. R. The mechanism of action of cyclosporin A and FK506. Immunol. Today 1992, 73, 136-142.
36. (a) Sabatini, D. M.; Erdjumentbromage, H.; Lui, M.; Tempst, P.; Snyder, S. H. RAFT: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78, 35-43.
37. (b) Dumont, F. J.; Su, Q. X. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 1996, 58, 373-395.
38. (c) Thomas, G.; Hall, M. N. TOR signaling and control of cell growth. Curr. Opin. Cell Biol. 1997, 9, 782-787.
39. (d) Brown, E. J.; Albers, M. N.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.; Schreiber, S. L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369, 756-758.
40. (e) Chiu, M. I.; Katz, H.; Berlin, V. RAPT1, a mammalian homologue of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12574-12578.
41. (a) Birkenshaw, T. N.; Caffrey, M. V.; Cladingboel, D. E.; Cooper, M. E.; Donald, D. K.; Furber, M.; Hardern, D. N.; Harrison, R. P.; Marriott, D. P.; Perry, M. W. D.; Stocks, M. J.; Teague, S. J.; Withnall, W. J. Synthetic FKBP12 ligands. Design and synthesis of pyranose replacements. Bioorg. Med. Chem. Lett. 1994, 4, 2501-2506.
42. (b) Armistead, D. M.; Badia, M. C.; Deininger, D. D.; Duffy, J. P.; Saunders: J. O.; Tung, R. D.; Murcko, M. A.; Yamashita, M. M.; Navia, M. A. Design, synthesis and structure of nonmacrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystallogr. 1995, D51, 522-528.
43. (c) Holt, D. A.; Konialian-Beck, A. L.; Oh, H.-L.; Yen, H.-K.; Rozamus, L. W.; Krog, A. J.; Erhard, K. F.; Ortiz, E.; Levy, M. A.; Brandt, M.; Bossard, M. J.; Luengo, J. I. Structure-activity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors. Bioorg. Med. Chem. Lett. 1994, 4, 315-320.
44. (d) Hamilton, G. S.; Steiner, J. P. Neuroimmunophilin ligands as novel therapeutics for the treatment of degenerative disorders of the nervous system. Curr. Pharm. Des. 1997, 3, 405-428.
45. (e) Lamb, M. L.; Jorgensen, W. L. Investigations of neurotrophic inhibitors of FK506 binding protein via Monte Carlo simulations. J. Med. Chem. 1998, 41, 3928-3939.
46. Hauske, J. R.; Dorff, P.; Julin, S.; DiBrino, J.; Spencer, R.; Williams, R. J. 1992 Design and synthesis of novel FKBP inhibitors. J. Med. Chem. 1992, 35, 4284-4296.
47. (a) Duffi, J. P. Novel immunosuppressive compounds. International Patent Application WO 92/21313, 1992.
48. (b) Reference 18c.
49. Dragovich, P. S.; Barker, J. E.; French, J.; Imbacuan, M.; Kalish, V. J.; Kissinger, C. R.; Knighton, D. R.; Lewis, C. T.; Moomaw, E. W.; Parge, H. E.; Pelletier, L. A.; Prins, T. J.; Showalter, R. E.; Tatlock, J. H.; Tucker, K. D.; Villafranca, J. E. Structure-based design of novel, urea-containing FKBP12 inhibitors. J. Med. Chem. 1996, 39, 1872-1884.
50. (a) Gold, B. G.; Zeleny-Pooley, M.; Wang, M.-S.; Chaturvedi, P.; Armistead, D. M. A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp. Neural. 1997, 147, 269-278.
51. (b) Constantini, L. C.; Chaturvedi, P.; Armistead, D. M.; Mccaffrey, P. G.; Deacon, T. W.; Isacson, O. A novel immunophilin ligand-distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinsons-disease. Neurobiol. Disease 1998, 5, 97-106.
52. (c) Gold, B. G.; Zelenypooley, M.; Chaturvedi, P.; Wang, M. S. Oral administration of a nonimmunosuppressant FKBP-12 ligand speeds nerve regeneration. Neuroreport 1998, 9, 553-558.
53. (a) Gold, B. G.; Katoh, K.; Storm-Dickerson, T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J. Neurosci. 1995, 15, 7509-7516.
54. (b) Gold, B. G. FK506 and the role of immunophilins in nerve regeneration. Mol. Neurol. 1997, 15, 285-306.
55. (c) Wang, M.-S.; Zeleny-Pooley, M.; Gold, B. G. Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve. J. Pharmacol. Exp. Ther. 1997, 282, 1084-1093.
56. (a) Sharkey, J.; Butcher, S. P. Immunophilins mediate the neuroprotective effects of FK506 in focal ischemia. Nature 1994, 371, 336-339.
57. (b) Hamilton, G. S.; Huang, W.; Connolly, M. A.; Ross, D. T.; Guo, H. L.; Valentine, P. D.; Suzdak, P. D.; Steiner, J. P. FKBP12-binding domain analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of parkinson's disease. Bioorg. Med. Chem. Lett. 1997, 7, 1785-1790.
58. (c) Hamilton, G. S. Immunophilin ligands for the treatment of neurological disorders. Exp. Opin. Ther. Patents 1998, 9, 1109-1124.
59. (d) Moriwaki, A.; Lu, Y.-F.; Tomizawa, K.; Matsui, H. An immunosuppressant, FK506, protects against neuronal dysfunction and death but has no effect on electrographic and behavioral activities induced by systemic kainate. Neuroscience 1998, 86, 855-865.
60. (e) Steiner, J. P.; Connolly, M. A.; Valentine, H. L.; Hamilton, G. S.; Dawson, T. M.; Hester, L.; Snyder, S. H. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nature Med. 1997, 3, 421-428.
61. (f) Snyder, S. H.; Sabatini, D. M.; Lai, M. M.; Steiner, J. P.; Hamilton, G. S.; Suzdak, P. D. Neural actions of immunophilin ligands. TiPS 1998, 19, 21-25.
62. (g) Hamilton, G. S.; Steiner, J. P. Immunophilins: Beyond immunosuppression. J. Med. Chem. 1998, 41, 5119-5143.
63. (25) Steiner, J. P.; Hamilton, G. S.; Ross, D. T.; Valentine, H. L.; Guo, H.; Connolly, M. A.; Liang, S.; Ramsey, C.; Li, J.-H. J.; Huang, W.; Howorth, P.; Soni, R.; Fuller, M.; Sauer, H.; Nowotnik, A. C.; Suzdak, P. D. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2019-2024.
64. Harper, S.; Bilsland, J.; Young, L.; Bristow, L.; Boyce, S.; Mason, G.; Rigby, M.; Hewson, L.; Smith, D.; Odonnell, R.; Oconnor, D.; Hill, R. G.; Evans, D.; Swain, C.; Williams, B.; Hefti, F. Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. Neuroscience 1999, 88, 257-267.
65. For a review on cycloheximide chemistry, see: Johnson, F. The chemistry of glutarimide antibiotics. Fortschr. Chem. Org. Naturst. 1971, 29, 1401.
66. (a) For a review on cycloheximide isolation, biosynthesis, and properties, see: Lost, J. L.; Kominek, L. A.; Hyatt, G. S.; Wang, H. Y. Cycloheximide: properties, biosynthesis, and fermentation. Drugs Pharm. Sci. 1984, 22, 531-550.
67. (b) Hardesty, B.; Obrig, T.; Irvin, J.; Culp, W. The effect of sodium fluoride, edeine, and cycloheximide on peptide synthesis with reticulocyte ribosomes. Basic Life Sci. 1973, 1, 377-392.
68. (c) Obrig, T. G.; Culp, W. J.; McKeehan, W. L.; Hardesty, B. The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J. Biol. Chem. 1971, 246, 174-181.
69. (a) Castagne, V.; Clarke, P. G. H. Inhibition of glutathione synthesis can enhance cycloheximide-induced protection of developing neurons against axotomy. Dev. Brain Res. 1997, 102, 285-290.
70. (b) Kharlamov, A.; Joo, J. Y.; Uz, T.; Manev, H. Cycloheximide reduces the size of lesion caused by a photothrombic model of brain injury. Neurol. Res. 1997, 19, 92-96.
71. (c) Fukukawa, K.; Estus, S.; Fu, W. M.; Mark, R. J.; Mattson, M. P. Neuroprotective action of cycloheximide involves induction of Bcl-2 and antioxidant pathways. J. Cell Biol. 1997, 136, 1137-1149.
72. (d) Imaizumi, K.; Tsuda, M.; Imai, Y.; Wanaka, A.; Takagi, T.; Tohyama, M. Molecular cloning of a novel polypeptide, DP5, induced during programmed neuronal death. J. Biol. Chem. 1997, 272, 18842-18848.
73. Millesi, H.; Berger, A.; Meissl, G. Experimentelle Untersuchungen zur Heilung durchtrennter peripherer Nerven. Chir. Plastica (Berlin) 1972, 1, 174-206.
74. Kornfeld, E. C.; Reuben, G.; Parke, T. V. The structure and chemistry of actidione, an antibiotic from Streptomyces griseus. J. Am. Chem. Soc. 1949, 71, 150-159.
75. Piatak, D. M.; Tang, P. L.; Yea, C.-C. Cycloheximide analogues as potential anticonvulsants. J. Med. Chem. 1986, 29, 50-54.
76. Johnson, F.; Starkovsky, N. A.; Paton, A. C.; Carlson, A. A. The total synthesis of cycloheximide. J. Am. Chem. Soc. 1966, 88, 149-159.
77. Heinze, S.; Ritzau, M.; Ihn, W.; Hülsmann, H.; Schlegel, B.; Dornberger, K.; Fleck, W. F.; Zerlin, M.; Christner, C.; Gräfe, U.; Küllertz, G.; Fischer, G. Lipohexin, a new inhibitor of prolyl endopeptidase from Moeszia lindtneri (HKI-0054) and Paecilomyces sp. (HKI-0055; HKI-0096). I. Screening, isolation and structure elucidation. J. Antibiot. 1997, 50, 379-383.
78. Gräfe, U.; Schlegel, R.; Ritzau, M.; Ihn, W.; Dornberger, K.; Stengel, C.; Fleck, W. F.; Gutsche, W.; Härtl, A.; Paulus, E. F. Aurantimycins, new depsipeptide antibiotics from Streptomyces aurantiacus IMET 43917. Production, isolation, structure elucidation, and biological activity. J. Antibiot. 1995, 48, 119-125.
79. Nishigori, H.; Mizumura, M.; Iwatsuru, M. The hen's fertile egg screening test (HEST): a comparison between the acute toxicity for chick embryos and rodents of 20 drugs. Cell Biol. Toxicol. 1992, 8, 255-265.
80. For examples, see: (a) Petronini, P. G.; de Angelis, E.; Borghetti, A. F.; Wheeler, K. P. Osmotically inducible uptake of betaine via amino acid transport system A in SV-3T3 cells. Biochem. J. 1994, 300, 45-50.
81. (b) Akagawa, H.; Ishii, A.; Mizuno, S. Suppression of thermotolerance development through cycloheximide-induced negative control of stress protein gene expression. J. Biochem. 1998, 123, 226-232.
82. (c) Favit, A.; Grimaldi, M.; Nelson, T. J.; Alkon, D. L. Alzheimer's-specific effects of soluble beta-amyloid on protein kinase C-alpha and -gamma degradation in human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5562-5567.
83. (d) Gutierrez, M.; Fernandez, A. I.; Revuelta, M. P.; Cantabrana, B.; Hidalgo, A. Patial contribution of polyamines to relaxant effect of 17 alpha-estradiol in rat uterine smooth muscle. Gen. Pharmacol. 1998, 30, 71-77.
84. (e) Merlin, L. R.; Bergold, P. J.; Wong, R. K. Requirement of protein synthesis for group I mGluR-mediated induction of eleptiform discharges. J. Neurophys. 1998, 80, 989-993.
85. Kofron, J. L.; Kuzmic, P.; Kishore, V.; Colón-Bonilla, E.; Rich, D. H. Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry 1991, 30, 6127-6134.
86. Geyer, U.; Heinze, T.; Stein, A.; Klemm, D.; Marsch, S.; Schumann, D.; Schmauder, H.-P. Formation, derivatization and application of bacterial cellulose. Int. J. Biol. Macromol. 1994, 16, 343.